Publicacións nas que colabora con Carmen Guillén Ponce (11)

2024

  1. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2019

  1. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

  2. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

  3. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain

    Psycho-Oncology, Vol. 27, Núm. 6, pp. 1530-1537

2015

  1. El cáncer hereditario en mujeres

    Arbor: ciencia, pensamiento y cultura, Núm. 773

  2. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

2013

  1. Consenso en cáncer hereditario entre la Sociedad Española de Oncología Médica y las sociedades de atención primaria

    Semergen: revista española de medicina de familia, Núm. 5, pp. 259-266

2012

  1. Consenso en cáncer hereditario entre la Sociedad Española de Oncología Médica (SEOM) y las sociedades de atención primaria: (SEMFYC, SEMERGEN y SEMG)

    Medicina general, Vol. 1, Núm. 7, pp. 33-34

2008

  1. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain

    Clinical Cancer Research, Vol. 14, Núm. 9, pp. 2861-2869